Tricuspid stenosis risk factors
|
Tricuspid stenosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tricuspid stenosis risk factors On the Web |
|
American Roentgen Ray Society Images of Tricuspid stenosis risk factors |
|
Risk calculators and risk factors for Tricuspid stenosis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Salih, M.D. Syed Musadiq Ali M.B.B.S.[2] Vamsikrishna Gunnam M.B.B.S [3]
Risk factors
Tricuspid stenosis (TS) is a rare valvular lesion without an independent atherosclerotic-type risk-factor profile. Clinically relevant risk factors are therefore largely conditions or exposures that predispose to structural tricuspid valve disease. TS almost always occurs with tricuspid regurgitation (TR), and rheumatic TS commonly coexists with left-sided rheumatic valve disease, particularly mitral stenosis. [1][2]
Established risk factors
Rheumatic heart disease
Rheumatic heart disease (RHD) is the dominant risk factor and cause of TS, accounting for approximately 90% of cases. [3]
Important upstream risk factors include:
- Recurrent acute rheumatic fever.
- Untreated or inadequately treated group A streptococcal pharyngitis.
- Residence in or origin from regions with a high burden of RHD.
- Crowding and limited access to primary and secondary antibiotic prophylaxis.
- Established left-sided rheumatic valve disease, particularly mitral stenosis. The presence of rheumatic mitral disease should prompt assessment of the tricuspid valve for coexisting TS/TR. [4][5]
Non-rheumatic predisposing conditions
Carcinoid heart disease
Carcinoid syndrome is an important non-rheumatic predisposition to right-sided valvular disease. More than 50% of patients with carcinoid syndrome develop carcinoid heart disease, predominantly involving the tricuspid and pulmonary valves. Tricuspid regurgitation is more common than TS, but stenotic involvement can occur. [6][7]
Right-sided valvular involvement predominates because serotonin and other vasoactive mediators are inactivated during passage through the pulmonary circulation. Left-sided involvement is uncommon and varies by clinical setting; reported estimates range from <10% in some series to approximately one-third in selected patients, particularly in the presence of an intracardiac right-to-left shunt or a bronchial primary tumor. The reported frequency should therefore be interpreted according to the underlying population and cited source rather than as a single fixed percentage. [8][9]
Congenital tricuspid valve abnormalities
Congenital structural abnormalities that can predispose to TS include:
- Ebstein anomaly.
- Congenital tricuspid valve dysplasia.
- Congenital TS or tricuspid atresia.
Congenital forms generally present earlier in life and may occur as part of complex congenital heart disease. [10][11]
Drug exposure
Exposure to recognized valvulopathic serotonergic or ergot-derived agents can predispose to tricuspid valve disease. Relevant exposures include:
- Fenfluramine and related anorectic agents.
- Methysergide and other ergot alkaloids.
A targeted medication and exposure history is appropriate when unexplained tricuspid valve disease is identified. [12][13]
Prosthetic tricuspid valve dysfunction
Patients with a previous tricuspid valve replacement are at risk for acquired prosthetic TS due to:
- Bioprosthetic degeneration.
- Mechanical or bioprosthetic valve thrombosis.
Prosthetic TS is an increasingly relevant clinical category as the number of patients undergoing tricuspid valve replacement increases. [14][15]
Cardiac implantable electronic devices
Indwelling right-heart hardware, including pacemaker and implantable cardioverter-defibrillator leads, can predispose to tricuspid inflow obstruction through:
- Device-associated thrombus.
- Lead-related fibrosis.
- Infective endocarditis with bulky vegetations.
New right-sided congestion in a patient with intracardiac hardware should prompt evaluation for device-related obstruction or endocarditis. [16]
Right atrial or tricuspid orifice masses
Right atrial myxoma and other right-heart mass lesions can mechanically obstruct the tricuspid orifice and produce TS-like inflow obstruction. These lesions represent mechanical obstruction rather than intrinsic rheumatic leaflet disease. [17][18]
Rare systemic and infiltrative diseases
Rare systemic or enzymatic disorders reported in association with tricuspid valve disease include:
Evidence for these associations is limited, and their magnitude of risk is not established. [19]
Clinically actionable risk assessment
- In patients with rheumatic mitral or aortic valve disease, assess the tricuspid valve for coexisting TS/TR.
- In patients with carcinoid syndrome, incorporate appropriate cardiac surveillance for right-sided valvular involvement.
- Obtain a targeted history of serotonergic and ergot-derived valvulopathic drug exposure.
- In patients with a previous tricuspid valve replacement who develop right-heart congestion, consider prosthetic degeneration or thrombosis.
- In patients with pacemaker or ICD leads and new right-sided congestion, consider device-related obstruction or endocarditis.
- Prevention of acute rheumatic fever and appropriate secondary antibiotic prophylaxis remain important population-level strategies for reducing rheumatic valve disease burden.
Evidence limitations
The relative contribution of rare systemic diseases and individual case-report associations to TS risk is poorly quantified. Antiphospholipid syndrome, systemic lupus erythematosus/Libman-Sacks disease, metastatic tumors, intravenous leiomyomatosis, blunt trauma, and ventriculoatrial shunts should not be treated as established TS risk factors on the basis of isolated case reports.
High-yield clinical pearls
- Isolated TS is rare; identification of TS should prompt assessment for coexisting TR and left-sided rheumatic valve disease.
- Rheumatic TS typically involves commissural thickening and fusion with chordal shortening rather than the heavy leaflet calcification characteristic of rheumatic mitral stenosis. [20]
- In carcinoid heart disease, right-sided valves are preferentially affected; left-sided involvement should raise consideration of an intracardiac right-to-left shunt or bronchial primary tumor. The reported frequency of left-sided involvement varies substantially between populations and should not be represented by a single blended estimate. [21][22]
- New right-heart failure in a patient with a tricuspid bioprosthesis or pacemaker/ICD lead should prompt evaluation for prosthetic or device-related TS.
Common pitfalls
- Attributing right-heart congestion solely to TR and missing coexisting TS, particularly in patients with rheumatic or post-mitral valve disease.
- Overweighting rare single-case-report associations as established TS risk factors.
- Failing to obtain a history of serotonergic or ergot-derived valvulopathic drug exposure.
References
- ↑ Asmarats et al. Nature Reviews Cardiology. 2019.
- ↑ 2025 ESC/EACTS Guidelines for the management of valvular heart disease. 2025.
- ↑ Asmarats et al. Nature Reviews Cardiology. 2019.
- ↑ 2020 AHA Scientific Statement on Rheumatic Heart Disease.
- ↑ 2008 ACC/AHA Focused Update for the Management of Patients With Valvular Heart Disease.
- ↑ Maleszewski et al. Journal of the American College of Cardiology. 2018.
- ↑ 2022 ESC Guidelines on cardio-oncology.
- ↑ Maleszewski et al. Journal of the American College of Cardiology. 2018.
- ↑ 2022 ESC Guidelines on cardio-oncology.
- ↑ Peters et al. Echocardiography. 2020.
- ↑ 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease.
- ↑ 2025 ESC/EACTS Guidelines for the management of valvular heart disease. 2025.
- ↑ 2008 ACC/AHA Focused Update for the Management of Patients With Valvular Heart Disease.
- ↑ Rodés-Cabau et al. Lancet. 2016.
- ↑ Peters et al. Echocardiography. 2020.
- ↑ 2025 ESC/EACTS Guidelines for the management of valvular heart disease. 2025.
- ↑ Rodés-Cabau et al. Lancet. 2016.
- ↑ 2008 ACC/AHA Focused Update for the Management of Patients With Valvular Heart Disease.
- ↑ 2025 ESC/EACTS Guidelines for the management of valvular heart disease. 2025.
- ↑ Asmarats et al. Nature Reviews Cardiology. 2019.
- ↑ Maleszewski et al. Journal of the American College of Cardiology. 2018.
- ↑ 2022 ESC Guidelines on cardio-oncology.